All In Biotech

Drug Trial Radar · NCT03575871

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 391 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

391

Actual

Start

Jun 29, 2018

Primary completion

Aug 13, 2019

Study completion Aug 13, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.

Conditions

  • Dermatitis, Atopic

Interventions

  • PF-04965842 100 mgDrug

    PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks

  • PF-04965842 200 mgDrug

    PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks

  • PlaceboDrug

    Placebo, administered as two tablets to be taken orally once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12Time frame: Baseline, Week 12
  2. Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12Time frame: Baseline, Week 12

Locations

115 sites in 13 countries. Site status is shown where the registry gives one.

  • Emmaus Research Center, Inc.

    Anaheim, California

  • Advanced Research Center, Inc. - Los Alamitos Site

    Los Alamitos, California

  • Peninsula Research Associates, Inc.

    Rolling Hills Estates, California

  • Clinical Science Institute

    Santa Monica, California

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado

  • Colorado Springs Dermatology Clinic, PC

    Colorado Springs, Colorado

  • Olympian Clinical Research

    Clearwater, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Precision Imaging

    Jacksonville, Florida

  • Solutions Through Advanced Research, Inc.

    Jacksonville, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Imaging Center of Idaho

    Caldwell, Idaho

  • ASR, LLC

    Nampa, Idaho

  • Meridian Clinical Research

    Baton Rouge, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Sadick Research Group

    New York, New York

  • PMG Research of Wilmington, LLC

    Wilmington, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • The Ohio State University Dermatology East

    Gahanna, Ohio

  • Tanenbaum Dermatology Center

    Memphis, Tennessee

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee

  • Austin Institute for Clinical Research, Inc. - Central

    Austin, Texas

  • Center for Clinical Studies, LTD. LLP

    Houston, Texas

  • West Houston Dermatology, PA

    Houston, Texas

  • Summit Clinical Research, LLC

    Franklin, Virginia

  • Virginia Dermatology and Skin Cancer Center

    Norfolk, Virginia

  • Australian Clinical Research Network

    Maroubra, New South Wales, Australia

  • The Skin Centre

    Benowa, Queensland, Australia

  • Veracity Clinical Research Pty Ltd

    Woolloongabba, Queensland, Australia

  • Skin and Cancer Foundation Inc

    Carlton, VIC 3053, Australia

  • Sinclair Dermatology

    East Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • The Royal Children's Hospital (RCH)

    Parkville, Victoria, Australia

  • Medical Centre Asklepii OOD

    Dupnitsa, Bulgaria

  • MHAT Dr. Tota Venkova AD

    Gabrovo, Bulgaria

  • "Acibadem City Clinic MHAT Tokuda" EAD

    Sofia, Bulgaria

  • "DCC Aleksandrovska" EOOD

    Sofia, Bulgaria

  • Diagnostic Consultative Center Fokus-5

    Sofia, Bulgaria

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.